Q: What is Treanda used for?

Treanda is used to treat chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma .

Q: How does Treanda work?

Mechanism of Action Treanda belongs to a group of drugs called alkylating agents. It is designed to target and destroy cancer cells by interfering with their genetic material. The medication works through the following process: DNA Damage: Once inside the body, the drug attaches to the DNA strands within cancer cells. Cross-linking: It creates chemical bonds, or cross-links, between these DNA strands. This prevents the strands from separating, which is a necessary step for the cell to copy its DNA. Cell Death: Because the cancer cell cannot replicate its DNA, it is unable to divide and grow. This damage eventually triggers the cell to die. While Treanda affects both healthy and cancerous cells, it is particularly effective against cancer cells because they usually divide more rapidly and are less able to repair the damage caused by the medication.

Q: What are the active ingredients in Treanda?

The active ingredient in Treanda is bendamustine .

Q: What are the side effects of Treanda?

Common side effects of Treanda may include: Nausea Fatigue Vomiting and others. Always consult with a healthcare professional about potential side effects.

Q: What drug class is Treanda?

Treanda belongs to the alkylating agent drug class.

Q: What is the dosage of Treanda and how do I take it?

Administration Treanda is given as an infusion into a vein by a healthcare professional in a medical setting, such as a hospital or clinic. The infusion process typically takes between 30 and 60 minutes. Treatment Schedule This medication is usually administered in cycles. A common treatment pattern involves receiving the medication on two consecutive days, followed by a rest period of several weeks. The total number of cycles and the length of the rest period depend on the specific condition being treated and how the patient responds to the therapy. Missed Doses Because Treanda is administered by a healthcare provider, it is important to keep all scheduled appointments. If an appointment is missed, patients should contact their doctor or the medical facility immediately to reschedule the infusion.

Q: Is Treanda safe during pregnancy and breastfeeding?

Pregnancy Treanda may cause fetal harm when administered to a pregnant woman. Animal studies have shown that the medication can cause birth defects or pregnancy loss. It is important to discuss the potential risks with a healthcare provider before starting treatment. Patients of reproductive potential should follow these contraception guidelines: Females: Use effective birth control during treatment and for at least 6 months after the final dose. Males: Use effective birth control during treatment and for at least 3 months after the final dose if your partner can become pregnant. If pregnancy occurs during treatment, contact a healthcare provider immediately. Breastfeeding There is no information on whether Treanda is present in human breast milk or how it might affect a nursing infant. Because of the potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 1 week after the last dose.

Q: What is the FDA approval status of Treanda?

FDA Approved Indications Treanda (bendamustine hydrochloride) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of the following conditions: Chronic lymphocytic leukemia (CLL): It is indicated for the treatment of patients with CLL, though its comparative efficacy to first-line therapies other than chlorambucil has not been fully established. Indolent B-cell non-Hodgkin lymphoma (NHL): It is indicated for patients whose disease has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. FDA Safety Communications The FDA has issued a specific safety warning regarding the liquid formulation of Treanda (injection solution). This formulation contains N,N-dimethylacetamide (DMA), a solvent that can interact negatively with certain plastics. The FDA warns against using the Treanda injection solution with closed system transfer devices (CSTDs), adapters, or syringes that contain polycarbonate or acrylonitrile-butadiene-styrene (ABS). The interaction between the drug and these materials can cause: Device failure, including leaking, breaking, or cracking. Contamination of the drug product with plastic components. Potential skin or respiratory exposure risks for healthcare professionals. Healthcare providers are instructed to verify the compatibility of all administration equipment before use or to use the lyophilized powder formulation of Treanda, which does not contain DMA and is not subject to this specific device warning.

Question 1

What is Treanda?

Accepted Answer

Treanda is a medication classified as an alkylating agent. It functions by interfering with the DNA of cancer cells, which helps to slow or stop their growth and spread within the body.

This therapy is used as a form of chemotherapy to manage specific oncological conditions. By targeting the genetic material of rapidly dividing cells, it works to limit the progression of the disease.

Question 2

What is Treanda used for?

Accepted Answer

Treanda is used to treat chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma.

Question 3

How does Treanda work?

Accepted Answer

Mechanism of Action

Treanda belongs to a group of drugs called alkylating agents. It is designed to target and destroy cancer cells by interfering with their genetic material.

The medication works through the following process:

DNA Damage: Once inside the body, the drug attaches to the DNA strands within cancer cells.
Cross-linking: It creates chemical bonds, or cross-links, between these DNA strands. This prevents the strands from separating, which is a necessary step for the cell to copy its DNA.
Cell Death: Because the cancer cell cannot replicate its DNA, it is unable to divide and grow. This damage eventually triggers the cell to die.

While Treanda affects both healthy and cancerous cells, it is particularly effective against cancer cells because they usually divide more rapidly and are less able to repair the damage caused by the medication.

Question 4

What are the active ingredients in Treanda?

Accepted Answer

The active ingredient in Treanda is bendamustine.

Question 5

What are the side effects of Treanda?

Accepted Answer

Common side effects of Treanda may include:

Nausea
Fatigue
Vomiting
and others.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Treanda?

Accepted Answer

Treanda belongs to the alkylating agent drug class.

Question 7

What is the dosage of Treanda and how do I take it?

Accepted Answer

Administration

Treanda is given as an infusion into a vein by a healthcare professional in a medical setting, such as a hospital or clinic. The infusion process typically takes between 30 and 60 minutes.

Treatment Schedule

This medication is usually administered in cycles. A common treatment pattern involves receiving the medication on two consecutive days, followed by a rest period of several weeks. The total number of cycles and the length of the rest period depend on the specific condition being treated and how the patient responds to the therapy.

Missed Doses

Because Treanda is administered by a healthcare provider, it is important to keep all scheduled appointments. If an appointment is missed, patients should contact their doctor or the medical facility immediately to reschedule the infusion.

Question 8

Is Treanda safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Treanda may cause fetal harm when administered to a pregnant woman. Animal studies have shown that the medication can cause birth defects or pregnancy loss. It is important to discuss the potential risks with a healthcare provider before starting treatment.

Patients of reproductive potential should follow these contraception guidelines:

Females: Use effective birth control during treatment and for at least 6 months after the final dose.
Males: Use effective birth control during treatment and for at least 3 months after the final dose if your partner can become pregnant.

If pregnancy occurs during treatment, contact a healthcare provider immediately.

Breastfeeding

There is no information on whether Treanda is present in human breast milk or how it might affect a nursing infant. Because of the potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 1 week after the last dose.

Question 9

What forms and strengths does Treanda come in?

Accepted Answer

Treanda is supplied in two formats for intravenous administration:

Lyophilized Powder: This form comes in a vial and must be reconstituted and diluted before use.
Injection Solution: This form is a concentrated liquid in a vial that must be diluted before administration.

Both forms are intended for use by a healthcare provider and are given as an infusion into a vein.

Question 10

What is the FDA approval status of Treanda?

Accepted Answer

FDA Approved Indications

Treanda (bendamustine hydrochloride) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of the following conditions:

Chronic lymphocytic leukemia (CLL): It is indicated for the treatment of patients with CLL, though its comparative efficacy to first-line therapies other than chlorambucil has not been fully established.
Indolent B-cell non-Hodgkin lymphoma (NHL): It is indicated for patients whose disease has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

FDA Safety Communications

The FDA has issued a specific safety warning regarding the liquid formulation of Treanda (injection solution). This formulation contains N,N-dimethylacetamide (DMA), a solvent that can interact negatively with certain plastics.

The FDA warns against using the Treanda injection solution with closed system transfer devices (CSTDs), adapters, or syringes that contain polycarbonate or acrylonitrile-butadiene-styrene (ABS). The interaction between the drug and these materials can cause:

Device failure, including leaking, breaking, or cracking.
Contamination of the drug product with plastic components.
Potential skin or respiratory exposure risks for healthcare professionals.

Healthcare providers are instructed to verify the compatibility of all administration equipment before use or to use the lyophilized powder formulation of Treanda, which does not contain DMA and is not subject to this specific device warning.

Question 11

What should I know about Treanda and cost?

Accepted Answer

Factors Influencing Cost

The total cost of treatment with Treanda is determined by several factors:

Dosage and Frequency: The amount of medication needed is based on the patient's body size and the condition being treated.
Administration Fees: Treanda is given as an intravenous infusion by a healthcare professional. Costs typically include fees for the medical facility and the professional services required for administration.
Generic Availability: Bendamustine, the active ingredient in Treanda, is available as a generic medication, which may be less expensive than the brand-name version.

Insurance and Assistance

Most insurance plans cover Treanda, but out-of-pocket expenses like copays and deductibles vary. Some patients may qualify for financial assistance programs or co-pay cards provided by the manufacturer to help manage costs.

Treanda

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Treanda

Hospitals.net Disclosure